Estrella Immunopharma, Inc.: ARMISTICE CAPITAL, LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Armistice Capital, LLC disclosed a stake exceeding 5% in Estrella Immunopharma, Inc. via a Schedule 13G filing with the SEC (accession 0001172661-26-005224). The exact share count and percentage were not specified in the filing headline. The disclosure signals active institutional ownership in the clinical-stage immunotherapy company. Investors will watch for further 13G amendments or 13D filings that could indicate activist intent.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Armistice Capital, LLC, Estrella Immunopharma, Inc.